GBM Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Regulatory ProgressAdvancing regulatory review and completed inspections reduce key development hurdles for INO-3.11k. A potential approval could create the company’s first meaningful commercial product and establish a durable revenue base.
Platform ValidationPositive partner Phase III results provide external validation for Inovio’s DNA medicine platform. This may improve the credibility of its technology, support future partnering, and strengthen the pipeline beyond its lead candidate.
Operating Cost ControlSustained operating expense reductions can extend development runway and lower the funding required to advance the pipeline. Better cost discipline is especially valuable for a pre-commercial biotechnology company with limited internal cash generation.
Bears Say
No Commercial RevenueThe absence of meaningful revenue leaves Inovio dependent on financing, partnerships, or future product approval to fund operations. Persistent losses also show that the business has not yet demonstrated a self-sustaining commercial model.
Liquidity And Funding RiskLimited runway creates a continuing need to manage spending and potentially raise additional capital before commercial cash flows are established. Further financing could dilute shareholders and constrain investment in pipeline development.
Regulatory Approval UncertaintyUncertainty over accelerated approval and confirmatory requirements could delay commercialization, increase development costs, or reduce the probability of near-term revenue. The unresolved regulatory pathway remains a material execution risk.
Inovio Pharmaceuticals News
GBM FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is CHF107.41M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 75 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -CHF0.056 earnings per share for the quarter, beating the consensus estimate of -CHF0.173 by CHF0.117.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.16.
How many shares outstanding does Inovio Pharmaceuticals have?
Currently, no data Available
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -CHF0.056 in its last earnings report, beating expectations of -CHF0.173. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in CH:GBM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF2.53 (― Upside)
CHF2.53 (― Upside)
Blogger Sentiment
Bullish
CH:GBM Sentiment 100%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-27.62%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen. This innovative approach is supported by its CELLECTRA smart device technology, which efficiently delivers the DNA plasmids. Inovio is actively engaged in and planning clinical trials for its DNA medicines across a wide array of conditions. These include HPV-related precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-driven cancers affecting areas like the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-associated disorders like recurrent respiratory papillomatosis. Beyond HPV, its pipeline addresses glioblastoma multiforme, prostate cancer, and a range of infectious diseases, including HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. The company benefits from a vast network of collaborators and partners, encompassing prominent academic institutions, government agencies, non-profit foundations, and pharmaceutical corporations. Key examples include AstraZeneca, The Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), the Defense Advanced Research Projects Agency (DARPA), the National Institutes of Health, Regeneron Pharmaceuticals, and the University of Pennsylvania. Significant partnerships also involve an agreement with Richter-Helm BioLogics GmbH & Co. KG to further develop the investigational COVID-19 DNA vaccine INO-4800, alongside a strategic alliance with the International Vaccine Institute and Seoul National University Hospital. Established in 1979, Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania.
GBM Company Deck
GBM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful progress on the regulatory front (target PDUFA date, completed inspections, an FDA informal meeting) and tangible commercial/pipeline milestones (partner Phase III success, DPROT preclinical progress, Syneos engagement). Financially the company cut costs and completed an $18.3M equity offering that extends runway into late Q1 2027. However, material risks remain: near‑term liquidity is tight with an $18M projected Q3 burn, net loss improvement was substantially driven by a noncash warrant gain, regulatory uncertainties persist around accelerated approval eligibility and confirmatory trial design feedback, and competitive uptake of a rival product exists. Taken together, positives around regulatory momentum and platform validation are balanced by financing, regulatory, and execution risks.View all CH:GBM earnings summaries